| 'No-One Is Safe until Everyone Is Safe'-Patent Waiver, Compulsory Licensing and COVID-19 B Kianzad, J Wested EPLR 5, 71, 2021 | 21 | 2021 |
| Kollaboration: vejen til åben forskning og åben innovation DB Pedersen, KM Martiny, AB Hansted, J Wested Samfundslitteratur, 2019 | 7 | 2019 |
| Has the EU incentive for drug repositioning been effective? An empirical analysis of the “+ 1” regulatory exclusivity J Liddicoat, K Liddell, M Aboy, J Wested IIC-International Review of Intellectual Property and Competition Law 52 …, 2021 | 5 | 2021 |
| Innovation and intellectual property policies in European Research Infrastructure Consortia—Part I: The Case of the European Spallation Source ERIC H Yu, J Blak Wested, T Minssen Journal of Intellectual Property Law & Practice 12 (5), 384-397, 2017 | 5 | 2017 |
| Standardization, IPRs and open innovation in synthetic biology T Minssen, JB Wested Innovation, competition and collaboration, 34-66, 2015 | 4 | 2015 |
| The role of patents and licensing in the governance of human genome editing: a white paper D Matthews, A Brown, E Gambini, T Minssen, A Nordberg, JS Sherkow, ... Queen Mary Law Research Paper, 2021 | 3 | 2021 |
| Research and Bolar Exemptions in the US and Europe: Recent Developments and Possible Scenarios J Wested, T Minssen Available at SSRN 3236127, 2018 | 1 | 2018 |
| Clearing a way through the CRISPR patent jungle T Minssen, E Van Zimmeren, J Wested Life Sciences Intellectual Property Review (LSIPR), 2018 | 1 | 2018 |
| Procedural Aspects of Compulsory Licensing Under TRIPS: Report No. II of Webinar Series on Reinterpreting TRIPS in the Life Sciences J Wested, T Minssen Available at SSRN 3043720, 2017 | 1 | 2017 |
| Applying Patents & Imaging Openness: Patenting Enabling Technologies in Synthetic Biology, the Case of CRISPR J Wested Det Juridiske Fakultet, Københavns Universitet, 2017 | 1 | 2017 |
| Lex Sex-Regulatory Perspectives on the Inclusion of Males and Females in Clinical Trials J Wested European Health & Pharmaceutical Law Review 7 (4), 158-172, 2024 | | 2024 |
| Imaginaries of the EU Commission Proposal for New the Pharmaceutical Regulation J Wested EHPL 7, 85, 2023 | | 2023 |
| The New Regulation of Health Technology Assessments J Wested EHPL 6, 122, 2022 | | 2022 |
| Repositioning for rare diseases–too much, too little or just right? J Wested, J Liddicoat NIR: Nordiskt Immateriellt Rättsskydd/Nordic Intellectual Property Law Review, 2021 | | 2021 |
| Repositioning for rare diseases–too much, too little or just right? J Liddicoat, J Wested | | 2021 |
| An Update on Research-& Bolar exemptions in the US and Europe: Unsolved questions and new developments in an increasingly important area of law J Wested, T Minssen NIR: Nordiskt immateriellt rättsskydd 2019 (2), 168-183, 2019 | | 2019 |
| Will the EPO’s Enlarged Board Hear the Broad’s CRISPR Case? J Wested, T Minssen, E Van Zimmeren Life Sciences Intellectual Property Review (LSIPR), 13.07, 2018 | | 2018 |
| TRIPS and the Life Sciences-Perspectives on Limitations to Patentability J Wested, T Minssen University of Copenhagen Faculty of Law Research Paper, 2017 | | 2017 |
| Preserving our Defences-Prudent and Appropriate Use of Antimicrobials 73 A Opalska, F Schmidt, C Fichet, M Lecaillon, J Wested, K Janssens, ... | | |
| The Italian Sunshine Act: New Transparency Rules for the Healthcare Sector 117 GR Mele, J Wested, C O'Keeffe, J Sugrue | | |
